Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer – guidance (TA654)

Osimertinib is recommended as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

Source:

National Institute for Health and Care Excellence